Literature DB >> 26898759

TRIMming p53's anticancer activity.

S Elabd1,2, G Meroni3, C Blattner1.   

Abstract

Several TRIM proteins control abundance and activity of p53. Along this route, TRIM proteins have a serious impact on carcinogenesis and prognosis for cancer patients. In the past years, a significant increase has been made in our understanding of how the TRIM protein family controls p53 activity.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26898759     DOI： 10.1038/onc.2016.33

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  76 in total

1.  Subclassification of the RBCC/TRIM superfamily reveals a novel motif necessary for microtubule binding.

Authors:  Kieran M Short; Timothy C Cox
Journal:  J Biol Chem       Date:  2006-01-23       Impact factor: 5.157

2.  MOZ increases p53 acetylation and premature senescence through its complex formation with PML.

Authors:  Susumu Rokudai; Oleg Laptenko; Suzzette M Arnal; Yoichi Taya; Issay Kitabayashi; Carol Prives
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

3.  PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2.

Authors:  Shutong Yang; Christin Kuo; John E Bisi; Myung K Kim
Journal:  Nat Cell Biol       Date:  2002-11       Impact factor: 28.824

4.  Novel breast cancer metastasis-associated proteins.

Authors:  Jiapei Ho; Jacklyn-Wai-Fun Kong; Lee-Yee Choong; Marie-Chiew-Shia Loh; Weiyi Toy; Poh-Kuan Chong; Chee-Hong Wong; Chow-Yin Wong; Nilesh Shah; Yoon-Pin Lim
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

5.  Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth.

Authors:  Tomohiko Urano; Tomoyuki Saito; Tohru Tsukui; Masayo Fujita; Takayuki Hosoi; Masami Muramatsu; Yasuyoshi Ouchi; Satoshi Inoue
Journal:  Nature       Date:  2002-06-20       Impact factor: 49.962

6.  Tripartite motif protein 32 facilitates cell growth and migration via degradation of Abl-interactor 2.

Authors:  Satoshi Kano; Naoto Miyajima; Satoshi Fukuda; Shigetsugu Hatakeyama
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

7.  Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization.

Authors:  Lidong Wang; David G Heidt; Cheong J Lee; Huibin Yang; Craig D Logsdon; Lizhi Zhang; Eric R Fearon; Mats Ljungman; Diane M Simeone
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

8.  New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors.

Authors:  Stefanie Wittmann; Christina Wunder; Birgit Zirn; Rhoikos Furtwängler; Jenny Wegert; Norbert Graf; Manfred Gessler
Journal:  Genes Chromosomes Cancer       Date:  2008-05       Impact factor: 5.006

9.  TRIM8 anti-proliferative action against chemo-resistant renal cell carcinoma.

Authors:  Mariano Francesco Caratozzolo; Alessio Valletti; Margherita Gigante; Italia Aiello; Francesca Mastropasqua; Flaviana Marzano; Pasquale Ditonno; Giuseppe Carrieri; Hélène Simonnet; Anna Maria D'Erchia; Elena Ranieri; Graziano Pesole; Elisabetta Sbisà; Apollonia Tullo
Journal:  Oncotarget       Date:  2014-09-15

10.  Deconstructing PML-induced premature senescence.

Authors:  Oliver Bischof; Olivier Kirsh; Mark Pearson; Koji Itahana; Pier Giuseppe Pelicci; Anne Dejean
Journal:  EMBO J       Date:  2002-07-01       Impact factor: 14.012
View more
  21 in total

Review 1.  TRIM Proteins and Their Roles in Antiviral Host Defenses.

Authors:  Michiel van Gent; Konstantin M J Sparrer; Michaela U Gack
Journal:  Annu Rev Virol       Date:  2018-06-27       Impact factor: 10.431

Review 2.  TRIM family contribute to tumorigenesis, cancer development, and drug resistance.

Authors:  Ning Huang; Xiaolin Sun; Peng Li; Xin Liu; Xuemei Zhang; Qian Chen; Hong Xin
Journal:  Exp Hematol Oncol       Date:  2022-10-19

Review 3.  TRIM8: Making the Right Decision between the Oncogene and Tumour Suppressor Role.

Authors:  Mariano Francesco Caratozzolo; Flaviana Marzano; Francesca Mastropasqua; Elisabetta Sbisà; Apollonia Tullo
Journal:  Genes (Basel)       Date:  2017-11-28       Impact factor: 4.096

4.  MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1/p53 pathway.

Authors:  Yan Shu; Ligang Ren; Bo Xie; Zhen Liang; Jing Chen
Journal:  Oncotarget       Date:  2017-10-23

5.  β2-AR activation induces chemoresistance by modulating p53 acetylation through upregulating Sirt1 in cervical cancer cells.

Authors:  Hongyu Chen; Wei Zhang; Xiang Cheng; Liang Guo; Shuai Xie; Yuanfang Ma; Ning Guo; Ming Shi
Journal:  Cancer Sci       Date:  2017-06-14       Impact factor: 6.716

6.  TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer.

Authors:  Yan Yin; Jun Zhong; Si-Wei Li; Jian-Zhe Li; Min Zhou; Yin Chen; Yi Sang; Lijuan Liu
Journal:  Oncotarget       Date:  2016-12-27

Review 7.  Tumor suppressor p53 cross-talks with TRIM family proteins.

Authors:  Juan Liu; Cen Zhang; Xue Wang; Wenwei Hu; Zhaohui Feng
Journal:  Genes Dis       Date:  2020-07-16

8.  TRIM52 inhibits Japanese Encephalitis Virus replication by degrading the viral NS2A.

Authors:  Wenchun Fan; Mengge Wu; Suhong Qian; Yun Zhou; Huanchun Chen; Xiangmin Li; Ping Qian
Journal:  Sci Rep       Date:  2016-09-26       Impact factor: 4.379

Review 9.  Census and evaluation of p53 target genes.

Authors:  M Fischer
Journal:  Oncogene       Date:  2017-03-13       Impact factor: 9.867

Review 10.  MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.

Authors:  Veronica Tisato; Rebecca Voltan; Arianna Gonelli; Paola Secchiero; Giorgio Zauli
Journal:  J Hematol Oncol       Date:  2017-07-03       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.